Our Team

Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master’s thesis on a survey of oncologists about smoked marijuana vs.…

Amy Emerson is the Chief Executive Officer at the MAPS Public Benefit Corporation (MAPS PBC), a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) non-profit. As the Chief Executive Officer, Amy has led the growth and development of this new subsidiary and is responsible for overall global regulatory strategy and…

Independent Voting Member David Bronner is Cosmic Engagement Officer (CEO) of Dr. Bronner’s, the top-selling brand of natural soaps in North America and producer of a range of organic body care and food products. He is a grandson of company founder, Emanuel Bronner, and a fifth-generation soapmaker. David and Michael established Dr. Bronner’s as a…

Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master’s thesis on a survey of oncologists about smoked marijuana vs.…

Kris Lotlikar serves as the President of MAPS, overseeing financing and day-to-day operations globally. Since joining the organization, Kris helped standup MAPS Public Benefit Corporation as a leading psychedelic drug development company and raised over $80 million. Kris’s passion and expertise is in building high-performing organizations in nascent and innovative markets: climate solutions, cannabis, and…

Andrew “Mo” Septimus is an experienced entrepreneur with a track record of managing multimillion-dollar raises and budgets, complex projects, and teams. He has worked in private equity and acted as CFO in various industries. Mo brings a compassionate, outgoing, and resourceful leadership style, coupled with practical optimism and a sense of humor. He enjoys craft…

Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master’s thesis on a survey of oncologists about smoked marijuana vs.…

Amy Emerson is the Chief Executive Officer at the MAPS Public Benefit Corporation (MAPS PBC), a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) non-profit. As the Chief Executive Officer, Amy has led the growth and development of this new subsidiary and is responsible for overall global regulatory strategy and…

Gisselle Acevedo is a trauma-informed Marriage and Family therapist and works with people in traditionally marginalized communities. She has served as CEO and in other executive positions across both philanthropic and for-profit organizations, including AT&T, The Los Angeles Times, Para Los Niños, and Ackerman Institute for the Family. Gisselle has served on the boards of…

Amy Emerson is the Chief Executive Officer at the MAPS Public Benefit Corporation (MAPS PBC), a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) non-profit. As the Chief Executive Officer, Amy has led the growth and development of this new subsidiary and is responsible for overall global regulatory strategy and…

Michael Mullette is an experienced drug development and commercialization expert, currently serving as Chief Operating Officer at MAPS Public Benefit Corporation (MAPS PBC). Mullette most recently served as the Vice President and Managing Director of North America for Moderna, where he oversaw commercialization of the company’s COVID-19 vaccine during the height of the pandemic. 

Berra Yazar-Klosinski, Ph.D., is Chief Scientific Officer of the MAPS Public Benefit Corporation (MAPS PBC). Dr. Yazar-Klosinski is responsible for development of strategic, catalytic, and capacity-building activities to facilitate research on the risk/benefit profile of psychedelics in compliance with the global regulatory landscape. She has been actively involved in the various stages of nonclinical and…